Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. - Wikidata - wikimedia - TriplyDB

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

http://www.wikidata.org/entity/Q37028643

about

Fludarabine in the treatment of chronic lymphocytic leukemia: a review Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis.MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia.Predicting survival in chronic lymphocytic leukemia.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.Evidence of canonical somatic hypermutation in hairy cell leukemia Choosing first-line therapy for chronic lymphocytic leukemia.p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.Treatment options for high-risk chronic lymphocytic leukaemia.Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737 Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.Risk categories and refractory CLL in the era of chemoimmunotherapy.The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.Update on therapy of chronic lymphocytic leukemia.Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.Rituximab for the treatment of patients with chronic lymphocytic leukemia Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood.Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?Prognostic relevance of MYD88 mutations in CLL: the jury is still out.Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.

P2860

Q24645173-C83B8BCB-AEE4-47F3-AD24-42E4FE42D75A Q26775986-BB4B7FEC-F3B4-47B5-88F0-46939177F4FF Q28081162-49FF55F0-D80E-486F-A4B4-6696E6BA8B23 Q33794311-E88A57DC-714B-4E87-A0E7-A603B4A797F2 Q33856248-62343778-5EF8-46B1-8C00-6B2F182A5C4D Q33942272-35FAF49B-6EF3-479B-BBC2-C08ADD651793 Q33965688-406C1AEA-4678-4EF1-8935-D0FE185A1044 Q34257190-B22B1BBD-196D-48F2-9063-CDCFAC42BC41 Q34310845-FD0C1893-5E97-4607-BA9A-FE0CAFD196DA Q34519192-FB160C3D-31BF-48B0-8E55-5076278000F8 Q35001615-5DEE55F1-B40A-4702-A2A1-C1FF3B7AA994 Q35124844-4192D5B9-798B-44DD-986C-6E5BDF20BA97 Q35597328-637E6069-A54A-4C7B-A377-03B1A76A0991 Q35806293-99F108BC-6547-4FF5-87C6-323700351B79 Q36550468-D628172D-5E19-47B3-AC29-FAB4975E0CDC Q36557448-F89ED158-6423-43BC-B254-D7C2C671377C Q36597026-C3283582-A48E-4AC7-BA02-5693D0F86433 Q36612587-998B28FF-10B6-4A9D-9F3E-6F538A3C15F5 Q36629141-28DFDCA1-D002-4CE2-B8D4-B5D62A80E7BE Q36788133-7E4C306F-E532-46BB-B73B-85D4BA679379 Q36925185-A26CFD62-AE8E-41E1-8553-A5B85C9B60E5 Q37141887-298402C5-E9F4-45FE-A566-208C54207436 Q37638782-2E5A92E8-6522-4A7F-B808-1B02C9135A05 Q37659071-95655391-007C-496C-8F61-6441AD30547E Q37842484-FC43FCE3-D21E-472E-8999-091DCEE722FC Q38680890-C9E81163-9E6A-4E42-8949-819FFBA4C8ED Q38851368-04142E40-D1C9-47CF-9B03-9DE48CA02CA4 Q38997367-B7CB9355-0640-4181-829E-5A5E47F418DA Q39303346-881BBF64-D84E-49B0-8F5C-E03240B5C07B Q41241909-D4E4E69A-0344-411A-9443-8710BA08F94E Q42398649-7786B7B9-4B5A-4AA6-B94F-68DFC41F4629 Q42938336-AB453681-88E9-44C7-975D-EFA638D483F3 Q42962523-7D86137E-96BA-432C-91E8-854643ABFDB6 Q50569242-C7B053D2-466B-467B-BB58-711EC97C895C

P2860

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

http://www.wikidata.org/entity/Q37028643

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Relevance of the immunoglobuli ...... d chemoimmunotherapy regimens.

@en

Relevance of the immunoglobuli ...... d chemoimmunotherapy regimens.

@nl

type

label

Relevance of the immunoglobuli ...... d chemoimmunotherapy regimens.

@en

Relevance of the immunoglobuli ...... d chemoimmunotherapy regimens.

@nl

prefLabel

Relevance of the immunoglobuli ...... d chemoimmunotherapy regimens.

@en

Relevance of the immunoglobuli ...... d chemoimmunotherapy regimens.

@nl

P1433

Q37028643-B32217D5-D3FD-4531-8EA0-C2FA48988707

P1476

Q37028643-F553EA01-EF04-43C7-A5E7-DF03235A39B9

P2093

Q37028643-10359F66-E7E9-458E-9210-1D64EA01CF85

Q37028643-3C8CE6FD-7A87-4CB5-862B-95F4821DF144

Q37028643-46BAE276-9ECD-4FC7-AB01-AD8DE1A0AE2B

Q37028643-85C92094-9FD2-4672-B9DE-FDF8FEBC91A3

Q37028643-C8FF8BEC-B73C-4AD8-B719-B883AB33251B

Q37028643-EE239C08-A304-4480-9475-7BD586E26680

Q37028643-FBD99D64-542A-4E15-B973-80B0A6FB59CE

P2860

Q37028643-065E8231-4FD2-4DC1-B522-1B578C92195C

Q37028643-12272724-A54F-4217-92CE-EEB87310377A

Q37028643-31E4E61D-6C58-4D71-87A0-42CECC98DFC7

Q37028643-7F4D50EE-FD05-4BFE-BCA4-5A109A945D43

Q37028643-80E3AACB-2987-47C6-91B6-676AB7730B79

Q37028643-8422BDCC-8437-4B82-9152-B1C4DD4F8F95

Q37028643-D44EA156-84AF-427E-9F39-DD7C1CB71F02

Q37028643-D791FFE1-9614-4B2B-AFBE-9127097F661B

Q37028643-D8213453-9492-4294-BAFD-BF017A215988

P304

Q37028643-5062FE8F-D868-4B7F-B31E-4FB716BDEC80

P31

Q37028643-A1F1B565-E37C-475B-B076-60FB93676BC6

P356

Q37028643-DE9A09CC-A3FA-4E5D-8B75-33F10C2BEAFE

P407

Q37028643-7CA4C760-019C-483E-B794-93377C41AAE8

P433

Q37028643-F8EFE6B0-E37C-471D-A073-56568C67AC3E

P478

Q37028643-AED8D21E-5C9C-44E4-8B34-75314AAF9459

P50

Q37028643-33409BA3-F426-4E9B-AA25-3AAF3450D9D2

Q37028643-64A8F28E-BA9F-4013-9E8F-F78BF80B53BD

Q37028643-9025E8DF-C91E-452E-B8B0-9CD2425E99E1

Q37028643-A4FFF0AA-6F2B-43F4-97BA-579AC70FF623

Q37028643-B4E5CDF0-DD1A-48AE-A508-22226DDF4B6D

Q37028643-CD4DEFC2-AB03-42C7-B39E-18152174B563

Q37028643-D25A4C0C-0A4A-4B95-A084-7B8953B327D1

Q37028643-F9143F50-54B6-4D5B-BEA6-C80C6C0E4569

P577

Q37028643-591CC7D8-CCE9-413F-81D8-BD2F452AB7B4

P5875

Q37028643-48B08D5C-8CA6-4BEE-B94C-58CC65FB5B31

P698

Q37028643-F9A442A4-C685-4E52-BF13-25A45EABAEF5

P921

Q37028643-21B6935C-31A4-4D4E-81A8-9C84060C63F7

Q37028643-87AE56B5-6D87-4218-8040-17FB685E4299

Q37028643-9433458B-237B-4B57-BDA2-8D6AA6C9AB12

P932

Q37028643-D43C1AD6-C969-4451-9D7F-AD00FAA09407

P356

BLOOD-2008-10-184853

P1433

P1476

Relevance of the immunoglobuli ...... d chemoimmunotherapy regimens.

@en

P2093

Constantine S Tam

http://www.w3.org/2001/XMLSchema#string

Ellen Schlette

http://www.w3.org/2001/XMLSchema#string

Katherine I Lin

http://www.w3.org/2001/XMLSchema#string

Laura Rassenti

http://www.w3.org/2001/XMLSchema#string

Lynn L Barron

http://www.w3.org/2001/XMLSchema#string

Lynne V Abruzzo

http://www.w3.org/2001/XMLSchema#string

Thomas J Kipps

http://www.w3.org/2001/XMLSchema#string

P2860

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome.

BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells.

P304

3168-3171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-10-184853

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Kevin R. Coombes

Hagop Kantarjian

Alessandra Ferrajoli

William G Wierda

Michael J. Keating

P577

2008-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23563345

http://www.w3.org/2001/XMLSchema#string

P698

19050308

http://www.w3.org/2001/XMLSchema#string

P921

P932

4916943

http://www.w3.org/2001/XMLSchema#string